

UK LLC NHS Digital Review Meeting Minutes

9-10am Monday 27th June 2022

UK LLC STAFF IN ATTENDANCE	
Andy Boyd – Chair	UK LLC Director
Stela McLachlan	UK LLC Research Manager
Rich Thomas	UK LLC Senior Data Manager
Katharine Evans	UK LLC Governance and Policy Manager
Diane Foster	UK LLC Senior Research Administrator
UK LLC VANGUARD MEMBERS IN ATTENDANCE	
Andrew Wong	MRC Unit for Lifelong Health and Ageing at UCL: 1946 NSHD and SABRE
Mark Mumme	ALSPAC
Daniel McCartney	Generation Scotland
Lynn Cherkas	Twins UK

Actions:

#029 UK LLC to contact the researcher's chair to see if there is support the UK LLC or wider LHW network could bring, to help them with this and to provide key information to bring in a wider set of studies in.

#030: UK LLC to inform llc_0015 researcher about existing UK LLC work to harmonise core SES indicators which will be integral to their application.

#031 UK LLC to make llc_0015 researcher aware of encryption of geographical indicators.

#032 UKLLC to advise llc_0015 to be aware that deprivation measures may have changed.

#033 Researcher llc_0025 to revise the lay summary to tie the term 'metabolomics' (used in the title) into the lay summary to ensure this is clear to a reader.

#034 llc_0025 researcher to refine the text to justify the need for using COVID-19 outcome and vaccine data (which is understood and approved, but could be more transparent in the text).

#035 llc_0025 researcher to improve the clarity on the range of metabolomics (beyond the 'Nightingale' chip) to be used and to upgrade their methodology.

#036 UK LLC to consider the wording on the template form regarding legal basis and to bring back options regarding ensuring clarity of this in past and future applications to the Committee for a decision.

Agenda Number	Presenter	Agenda Item	Action Points
1.	All	Introduction	
2.	All	<p>Application: llc_0015 Title: “Socio-demographic determinants of COVID-19” Primary Applicant: Olivia Hamilton</p> <p>The application was considered to be clear with a strong justification and in line with the interdisciplinary nature of UK LLC and with the LHW brief. The case for potential benefits to the Health and Social Care system was considered to be strong.</p> <p>The panel discussed the potential for using a broader set of studies – which are likely to have relevant data - and whether the absence of these related to lack of clarity regarding data availability or other barriers (e.g., researcher capacity to harmonise across many studies). The panel agreed the UK LLC should raise this with the applicants and discuss options.</p> <p>The panel also agreed the UK LLC should advise to the applicants about the use of harmonised SES indicators (outputs from llc_001 and llc_0002) and encrypted geographical indicators to support their study.</p> <p>Summary:</p> <ul style="list-style-type: none"> • Additional studies including ALSPAC, EXCEED, GLAD and EPIC could provide relevant data. • The range of socioeconomic demographic indicators, overlaps with the harmonization project (llc_001) could be re-used and bring efficiencies to the project. 	<p>#029 UK LLC to contact the researcher’s chair to see if there is support the UK LLC or wider LHW network could bring, to help them with this and to provide key information to bring in a wider set of studies in</p> <p>#030: UK LLC to inform llc_0015 researcher about existing UK LLC work to harmonise core SES indicators which will be integral to their application.</p> <p>#031 UK LLC to make llc_0015 researcher aware of encryption of geographical indicators.</p>

		<ul style="list-style-type: none"> • Geographical indicators are encrypted in the UK LLC but can support the inclusion of SES indicators which is being conducted by UK LLC (LLC core activity). The applicants should be made aware of this work as it could bring value and efficiency to the project. SES deprivation indicators vary over time and this should be made clear by the UK LLC to the applicant. • Consensus is that the application can be approved. 	<p>#032 UKLLC to advise llc_0015 to be aware that deprivation measures may have changed.</p>
3		<p><u>Application:</u> llc_0025 <u>Title:</u> “Using metabolomics to better understand COVID-19 symptoms” <u>Primary Applicant:</u> Francisco Perez-Reche</p> <p>Summary of points and feedback:</p> <p>The Committee considered that the application was clear with a strong justification and in line with the aims of the LHW NCS and the UK LLCs approved purpose. The case for potential benefits to the Health and Social Care system was considered to be strong.</p> <p>It might be confusing for participants to have a technical term like metabolomics in the title and then not explained in the lay summary.</p> <p>Summary:</p> <ul style="list-style-type: none"> • There is a clear need for using COVID outcome and vaccine data in the application. Applicant should refine the text to clarify this and to justify their inclusion. • The researcher must improve the clarity on the range of metabolomics to be used and to upgrade their methodology. • Consensus is that the application is approved subject to clarification on the methodology on the use of metabolomics 	<p>#033 Researcher llc_0025 to revise the lay summary to tie the term ‘metabolomics’ (used in the title) into the lay summary to ensure this is clear to a reader.</p> <p>#034 llc_0025 researcher to refine the text to justify the need for using COVID-19 outcome and vaccine data (which is understood and approved, but could be more transparent in the text).</p> <p>#035 llc_0025 researcher to</p>

		<p>and the revised form should be circulated to all committee members.</p>	<p>improve the clarity on the range of metabolomics (beyond the 'Nightingale' chip) to be used and to upgrade their methodology.</p>
6		<p>Correction needed to template form:</p> <p>The UK LLC application form provides stock answers for some fields that are consistent across all LHW NCS projects. The justification for the legal basis for UK GDPR Article 9 is potentially confusing to a reader and should be adapted. A new stock text of 'the longitudinal community have agreed, following consultation with MRC regulatory experts, that compliance with Article 9 is based on conducting scientific or historical research purposes or statistical purposes (Article 9(2)(j) in accordance with Article 89(1)).' Adapting this will make clear the distinction for our basis in using Article 9(2)(j) from the use of studies of consent or s251 of the NHS Act 1996 to meet Common Law Duty of Confidentiality.</p> <p>The Committee discussed the importance of making this basis clear to readers and discussed the merits of making a retrospective change (at an Executive level rather than requiring applicants to submit amendments) and the risk this may then cause conflicts with copies of applications held by studies.</p> <p>UK LLC will refine the wording on the form and bring back options regarding any retrospective change to the next meeting for a decision as to how to proceed.</p>	<p>#036 UK LLC to consider the wording on the template form regarding legal basis and to bring back options regarding ensuring clarity of this in past and future applications to the Committee for a decision.</p>